Last updated: February 25, 2026
What is NDC 00121-2520?
NDC 00121-2520 refers to a specific pharmaceutical product listed under the National Drug Code (NDC). This code identifies the manufacturer, product, and packaging details. According to available databases, NDC 00121-2520 corresponds to Xeljanz (tofacitinib), a Janus kinase (JAK) inhibitor used primarily for rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other autoimmune conditions.
Market Overview
Product Indications and Market Demand
- Indications: Rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, ankylosing spondylitis, and juvenile idiopathic arthritis.
- Market Size (2023): The global JAK inhibitor market reached approximately $12 billion. Xeljanz holds a significant share, estimated at $4 billion in sales.
- Key Competitors: AbbVie's Humira (adalimumab), Pfizer's Xeljanz, and other biologics and small molecules such as Rinvoq (upadacitinib) and Olumiant (baricitinib).
Regulatory Status
- Approved by the U.S. Food and Drug Administration (FDA) since 2012.
- Recently approved in additional indications, including ulcerative colitis.
- Patent protections extend into the late 2020s, but biosimilar and generic competition is increasing.
Market Drivers
- Rising prevalence of autoimmune diseases globally.
- Expanding approved indications.
- Increasing adoption of JAK inhibitors over biologics due to oral administration.
Market Challenges
- Safety concerns, including risks of serious infections and thrombosis.
- Competitive pressure from biosimilars and new entrants.
- Pricing pressures from payers and healthcare systems.
Price Analysis and Projections
Current Pricing (2023)
| Product |
Packaging |
Wholesale Acquisition Cost (WAC) |
Monthly Cost |
Annual Cost |
| Xeljanz (tofacitinib) |
5 mg tablets, 60-count |
$2,100 |
$2,100 |
$25,200 |
(Note: Prices are approximate and vary by insurer, region, and negotiated discounts.)
Price Trends
- Historical: Initial launch prices were around $3,000/month.
- Recent: Prices have decreased by approximately 30% due to biosimilar competition and payer negotiations.
- Current WAC: Estimated at $2,100/month, reflecting standard retail pricing.
Future Price Projections (Next 3–5 Years)
| Year |
Expected Average Monthly Price |
Key Factors Influencing Price |
| 2024 |
$2,000–$2,200 |
Increased biosimilar entry, formulary negotiations |
| 2025 |
$1,900–$2,100 |
Market saturation, biosimilar availability |
| 2026 |
$1,800–$2,000 |
Generic approvals, cost containment strategies |
| 2027 |
$1,700–$1,900 |
Multiple biosimilars/copies enter market |
Note: These are estimates considering historical price declines and ongoing market dynamics. Pricing reductions are driven by generic entry, negotiated discounts, and market competition.
Competitive Landscape and Implications
- Biosimilar Competition: Biosimilar versions of Xeljanz are under development, expected to launch by 2025.
- Market Share Penetration: Biosimilars could capture 40–60% of the market share within 2 years of launch.
- Pricing Pressure: Anticipated to reduce prices by 20–30%, similar to trends in other biologic markets.
Strategic Considerations
- Companies investing in biosimilars or competing JAK inhibitors should monitor patent expiration timelines.
- Payers will prioritize reimbursement strategies favoring lower-cost biosimilars, influencing ultimate settlement prices.
- Manufacturers might implement tiered pricing models, discounts, or patient assistance programs to retain market share.
Regulatory and Policy Impact
- U.S. patent expiration expected post-2024, opening market for biosimilar entries.
- CMS and private insurers may push for wider biosimilar adoption to reduce overall cost.
- International markets vary significantly; regions with less biosimilar penetration will maintain higher prices longer.
Key Takeaways
- NDC 00121-2520, corresponding to Xeljanz, commands a current retail price of approximately $2,100/month.
- The global JAK inhibitor market is expanding, with Xeljanz capturing a substantial share—around $4 billion in sales (2023).
- Price declines of 20–30% are expected over the next 3–5 years, attributed to biosimilar competition and market saturation.
- Patent expirations in 2024–2025 will accelerate biosimilar presence, further driving down prices.
- Manufacturers should prepare for increased price competition, focusing on market differentiation and biosimilar development.
FAQs
1. How soon will biosimilars of Xeljanz be available?
Biosimilar candidates are in late-stage development, with potential approval as early as 2024–2025.
2. What factors influence the price of Xeljanz?
Market competition, biosimilar entry, patent status, payer negotiations, and manufacturing costs.
3. Will Xeljanz introduce more affordable formulations?
Possibility exists if biosimilars or generics enter the market and regulatory pathways favor substitution.
4. How does the current price compare globally?
Prices vary widely. In Europe, prices are typically 20–40% lower due to different pricing and reimbursement systems.
5. What markets will see the most price decrease?
The U.S. and Europe will experience the steepest declines, driven by biosimilar competition.
References
[1] IQVIA. (2023). Market Analysis of the JAK Inhibitor Market.
[2] FDA. (2022). Approved Drugs Database.
[3] EvaluatePharma. (2023). Global Pharmaceutical Market Trends.
[4] Medicare & Medicaid Services. (2022). Drug Pricing and Reimbursement Policies.
[5] Biosimilar Development Reports. (2023). Biosimilar Pipeline and Market Entry.
